Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC

Neuro-oncology
Timothy F CloughesyTobias Walbert

Abstract

Vocimagene amiretrorepvec (Toca 511) is an investigational gamma-retroviral replicating vector encoding cytosine deaminase that, when used in combination with extended-release 5-fluorocytosine (Toca FC), results preclinically in local production of 5-fluorouracil, depletion of immune-suppressive myeloid cells, and subsequent induction of antitumor immunity. Recurrent high-grade glioma (rHGG) patients have a high unmet need for effective therapies that produce durable responses lasting more than 6 months. In this setting, relapse is nearly universal and most responses are transient. In this Toca 511 ascending-dose phase I trial (NCT01470794), HGG patients who recurred after standard of care underwent surgical resection and received Toca 511 injected into the resection cavity wall, followed by orally administered cycles of Toca FC. Among 56 patients, durable complete responses were observed. A subgroup was identified based on Toca 511 dose and entry requirements for the follow-up phase III study. In this subgroup, which included both isocitrate dehydrogenase 1 (IDH1) mutant and wild-type tumors, the durable response rate is 21.7%. Median duration of follow-up for responders is 35.7+ months. As of August 25, 2017, all responders r...Continue Reading

References

Oct 1, 1992·Neuropathology and Applied Neurobiology·V H Perry, P B Andersson
Jul 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D R MacdonaldJ G Cairncross
Sep 11, 2001·Seminars in Oncology·D R Macdonald
Oct 13, 2004·The Oncologist·Maitreyee HazarikaRichard Pazdur
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Jul 5, 2006·Neurosurgical Focus·A Sehgal, M S Berger
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henry S FriedmanTimothy Cloughesy
Feb 4, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wolfgang WickHoward A Fine
Mar 17, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick Y WenSusan M Chang
Nov 9, 2012·Neuro-oncology·Michael WellerWolfgang Wick
Dec 12, 2012·Nature Biotechnology·Cole TrapnellLior Pachter
Apr 4, 2015·Science·Ton N Schumacher, Robert D Schreiber
Sep 17, 2015·Cancer Cell·Jinkuk KimDo-Hyun Nam
Dec 17, 2015·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Alicia OrtegaChirag G Patil
Dec 25, 2015·Acta Neuropathologica Communications·Kaspar DraaismaPim J French
Mar 10, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F Stephen HodiJedd D Wolchok
Mar 24, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric BouffetUri Tabori
Jun 3, 2016·Science Translational Medicine·Timothy F CloughesyMichael A Vogelbaum
Jun 9, 2016·Journal of Neuro-oncology·Jacob J MandelJohn F de Groot
Jan 22, 2017·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Benjamin M EllingsonTimothy F Cloughesy
Sep 4, 2017·Current Oncology Reports·Karan Dixit, Priya Kumthekar

❮ Previous
Next ❯

Citations

Jan 25, 2019·Expert Opinion on Investigational Drugs·Brandon D Philbrick, D Cory Adamson
Feb 16, 2019·Cancers·Miika Martikainen, Magnus Essand
Jul 12, 2019·Nature Reviews. Drug Discovery·Kevin HarringtonJean-Charles Soria
Oct 11, 2019·Drugs·Rimas V LukasAdam M Sonabend
Apr 8, 2020·Journal of Neuro-oncology·Ravi MedikondaMichael Lim
Sep 5, 2020·The Journal of International Medical Research·Can ChenYanling Zhang
Sep 11, 2020·Neurologia Medico-chirurgica·Ryota Tamura, Masahiro Toda
Sep 29, 2020·Japanese Journal of Clinical Oncology·Takahide NejoHideho Okada
Feb 23, 2019·Current Treatment Options in Oncology·Tresa McGranahanSeema Nagpal
Jul 4, 2019·International Journal of Oncology·Stefanie MaurerSusanne Berchtold
May 21, 2019·Expert Review of Neurotherapeutics·Candice D CarpenterVinay K Puduvalli
Aug 10, 2019·Frontiers in Immunology·Andy S DingMichael Lim
Mar 19, 2020·International Journal of Molecular Sciences·Sabbir KhanJohn F de Groot
Nov 30, 2019·Neurosurgical Review·Ryota TamuraMasahiro Toda
Oct 31, 2018·Frontiers in Oncology·Kewal K Jain
Jan 22, 2020·Expert Opinion on Biological Therapy·David B AltshulerMaria G Castro
Sep 28, 2018·Nature·Michael Eisenstein
Mar 6, 2019·BMC Cancer·Arunas KazlauskasJaunius Urbonavičius
Jul 31, 2019·Nature Immunology·Christopher M JacksonMichael Lim
May 24, 2020·Current Neurology and Neuroscience Reports·Elisa K LiuSylvia C Kurz
Oct 27, 2020·The Oncologist·Edwin Nieblas-BedollaPriscilla K Brastianos
Aug 21, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·William P AccomandoDerek Ostertag
Jan 27, 2021·Current Oncology Reports·Abigail L MendeJennifer L Clarke
Dec 31, 2020·Cancers·Cristina BirzuGiuseppe Lombardi
Dec 17, 2020·Cancers·Oleg MozheiSergey Kasparov
Dec 18, 2020·Molecular Therapy : the Journal of the American Society of Gene Therapy·Evan K DayMatthew J Lazzara
Feb 10, 2021·Cancers·Eftychia StavrakakiMartine L M Lamfers
Oct 15, 2020·International Journal of Molecular Sciences·Jana de SostoaDenis Migliorini
Mar 17, 2021·Expert Opinion on Biological Therapy·Sara A CollinsDouglas J Jolly
Apr 2, 2021·Frontiers in Molecular Neuroscience·Kaushik BanerjeeMaria G Castro
May 1, 2021·International Journal of Molecular Sciences·Sanjeev ChawlaHarish Poptani

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.